Healthcare / Medical Care FacilitiesJakartaID
$316.00
-2.00 (-0.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-49.8B · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$837.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.6%
↓Gross Margin
16.7%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+51.3%
FCF CAGR
—
FCF margin
-43.5%
FCF / Net income
3.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $114.40B · net income $-16.42B · FCF $-49.77B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $114.40B | $114.40B | $48.50B | $42.16B | $33.03B |
| Net Income | $-16.42B | $-16.42B | $-3.51B | $-1.11B | $-7.35B |
| EPS | -6.20 | -6.20 | -1.33 | -0.42 | -2.78 |
| Gross Margin | 16.7% | 16.7% | 28.6% | 28.3% | 11.2% |
| Operating Margin | -9.8% | -9.8% | -6.5% | -3.4% | -26.6% |
| Net Margin | -14.4% | -14.4% | -7.2% | -2.6% | -22.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.23 | 0.00 | 1.31 |
| Current Ratio | 0.52 | 0.52 | 0.75 | 1.85 | 3.15 |
| Cash Flow | |||||
| Free Cash Flow | $-49.77B | $-49.77B | $-40.21B | $-71.57B | $-16.09B |
| Returns | |||||
| ROE | -12.6% | -12.6% | -2.4% | -0.7% | -19.6% |
| Growth & Yield | |||||
| Revenue Growth | 135.9% | 135.9% | 15.0% | 27.6% | — |
| EPS Growth | -367.5% | -367.5% | -215.9% | 84.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.33 → -6.20
Residual
-28.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.